Company intelligence / Profile preview

Après-demain

Ownership: Private
Employees: ~420
Development stage: Other

Overview

Après-demain is a Swiss private family-owned holding company with significant activities in life sciences through its main operating division, Debiopharm. The group’s focus in health includes oncology and infectious diseases. Its subsidiaries have brought multiple therapies to market—including two blockbusters for colon and prostate cancer—and maintain an active late-stage pipeline. The group also invests in digital health and smart data start-ups via the Debiopharm Innovation Fund.

Modalities: Small moleculeMonoclonal antibodyRadiopharmaceutical
Industry: Biotech

Partnerships

Merck KGaAITM Isotope Technologies Munich SEMSM Protein TechnologiesYale UniversityEvotec AGNobelex Biotech

Beyond the preview

Go deeper on Après-demain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Après-demain.

Explore the full profile